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Progenitor cells in the kidney: Biology and therapeutic per-
spectives. The stem cell may be viewed as an engineer who can
read the blue print and become the building. The role of this
fascinating cell in physiology and pathophysiology has recently
attracted a great deal of interest. The archetype of stem cells is
the zygote: one cell capable of endless proliferation and differ-
entiation into all tissue types in the human body. Historically,
the differentiation of embryonic stem cells is seen as an irre-
versible process with restricting possibilities for differentiation
leading finally to a terminally differentiated cell type. Stem cells
have also been described in the adult. They were first defined in
tissues with a high cell turnover like skin and gut. Today, stem
cells have also been shown in tissues with no or low regenerative
potential and turnover, like the kidney. Traditionally, adult stem
cells were thought to be restricted in their differentiative and
regenerative potential to the tissues in which they reside. How-
ever, the stem cell concept is changing rapidly as evidence is
mounting that adult stem cells not only reside locally in specific
niches, but may also be recruited from the circulation to actively
participate in the regeneration of various tissues. Furthermore,
reverse differentiation has been demonstrated. This means that
highly specialized cell types are able to dedifferentiate and en-
gage in stem cell like activities. Moreover, transdifferentiation
of mature cells into different cell types has been reported. This
paper will review our current knowledge on renal stem cells and
progenitor cells. Specifically, it will discuss the role of progenitor
cells and transdifferentiation in renal repair and maintenance.
Finally, the potential clinical implications of these findings will
be discussed.
Most renal diseases can be envisioned as the conse-
quence of a dysbalance between tissue damage and re-
pair. Hypoxia, infection, immune reactions, and toxic
substances can damage renal tissue. On the other hand,
regenerative mechanisms counteracting the damage in-
flicted on renal tissues have been reported as well, both
in tubuli (reviewed in [1]) and the glomeruli [2]. Insights
into the nature of these regenerative mechanisms have
evolved over the years. In tissues with a high cell turnover
like the gut or the hematopoietic system, organ- or tissue-
restricted stem cells have been shown to replace cells that
have completed their life cycle. It is becoming increas-
ingly apparent that in organs with a relatively low rate of
Key words: endothelial progenitor cells, multipotent adult progenitor
cells, vascular endothelial growth factor.
cellular turnover like the liver and kidney similar regen-
erative mechanisms are operational [3–5]. The cellular
players responsible for regenerative mechanisms in the
kidney include not only proliferating mature renal cells
but recent reports also suggest a renal role for stem cells,
both from local pools as well as from the circulation.
STEM CELLS OR PROGENITOR CELLS
Stem cells and progenitor cells are terms often used
and confused. By definition stem cells are clonogenic
cells capable of both self-renewal and multilineage differ-
entiation [6]. According to the classical view, these cells
become increasingly restricted in their differentiation po-
tential during proliferation and development. Progenitor
cells are defined as immature and proliferative cells which
are limited in their differentiation potential to only one
cell type. According to the classical view, the stem cell is
the multipotent ancestor of the unipotent progenitor cell.
Few studies have addressed the potential of multipo-
tent adult stem cells to differentiate into renal tissues. In
one of these experiments, Jiang et al [7] isolated a multi-
potent adult progenitor cell (MAPC) from adult murine
bone marrow and showed that these MAPC contributed
to virtually all somatic tissues of the developing embryos,
including several renal cell types, like endothelial and
tubular cells. Although this proof of principle is fascinat-
ing, the physiologic and clinical relevance of these multi-
potent stem cells is still uncertain. In these studies single
cell assays have been used to prove clonogenic expan-
sion and pluripotency of stem cells. In these assays single
cells are cultured and their progeny is differentiated into
various cell types. This extensive in vitro processing might
have influenced the cells in a nonphysiologic way, thereby
extending their developmental repertoire.
To study renal regeneration and maintenance, pluripo-
tency of the proliferating cells is not a primary issue that is
therefore not often addressed. Consequently, these cells
should be considered as progenitor cells. Most renal stud-
ies have focused on the role of progenitor cells in basal
cell turnover and repair in (reversible) renal injury mod-
els. Resident progenitor cells are typically identified using
techniques that trace foci of proliferating cells in con-
junction with immunohistochemical characterization of
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these cells. Participation of extrarenal progenitor cells is
mostly studied in renal or bone marrow transplantation
models, using methods to specifically stain for cells de-
rived from the kidney recipient or bone marrow donor.
Although transplantation experiments provide an excel-
lent tool to investigate whether extrarenal progenitors
contribute to renal regeneration, accurate quantification
of the extent to which these extrarenal progenitors partic-
ipate in this process may not be possible from this type of
experiment. The total body radiation required for bone
marrow transplantation experiments, combined with re-
jection involved in both transplantation models, may
cause increased damage and subsequently a higher renal
cell turnover. Furthermore, radiation might influence the
proliferating capacity of resident renal progenitor cells,
favoring the role of bone marrow–derived renal progen-
itor cells.
Notwithstanding the limitations of experimental ap-
proaches, evidence is accumulating suggesting that pro-
genitor cells play a role in maintenance and repair of the
adult kidney. In the following sections we will outline re-
cent observations supporting the existence of progenitors
for the major renal cell types.
INVOLVEMENT OF PROGENITOR
CELLS IN THE KIDNEY
Endothelium
The kidney harbors several different types of endothe-
lial cells, in particular the endothelium of the macrovas-
culature, the peritubular capillary endothelium, and the
glomerular endothelium. Besides participation in the fil-
tration, reabsorption, and nutrition of the renal tissue,
endothelial cells play a key role in recovery from several
renal diseases. The evident question therefore is whether
endothelial progenitor cells (EPC) can also participate
in regeneration and maintenance of these renal endothe-
lial cell types. Evidence for the existence of EPC has
mostly been derived from cardiovascular research on is-
chemia and angiogenesis [8]. Circulating progenitor cells
for endothelial cells were first shown by Asahara et al
[9]. In their experiments CD34+ leukocytes were isolated
from human adult peripheral blood. These cells were sub-
sequently cultured and differentiated into an endothe-
lial cell–like phenotype. That these EPC are different
from circulating mature endothelial cells was elegantly
shown by Lin et al [10]. In bone marrow transplant pa-
tients, circulating endothelial cells from both donor (bone
marrow–derived) and acceptor were cultured from pe-
ripheral blood. Interestingly, the bone marrow–derived
cells were markedly more mitogenic than the acceptor
cells and quickly outgrew circulating mature endothelial
cells. EPC can stimulate vascular repair processes in dif-
ferent ways. Several authors have shown that EPC are
involved in new vessel formation by incorporating in the
vessel wall [9]. Furthermore, EPC stimulate vessel for-
mation by secreting proangiogenetic factors like vascular
endothelial growth factor (VEGF) and basic fibroblast
growth factor (bFGF), which subsequently enhance pro-
liferation and migration of resident cells [11].
A number of studies have addressed maintenance and
regeneration of the specialized renal glomerular capillar-
ies. Pabst and Sterzel [3] have reported that, in normal
rats, the rate of total glomerular cell renewal is about 1%
per day with the endothelial fraction being the most pre-
dominant cell type. However, in response to injury, the
rate of vascular regeneration could well be increased. An
established model to study glomerular injury and repair
in rats is experimental anti-Thy1.1 glomerulonephritis.
Injection of a complement-fixing antibody to the mesan-
gial cell antigen Thy1.1 causes acute mesangiolysis and
matrix dissolution, leading to ballooning of glomerular
capillaries, formation of aneurysms, and loss of endothe-
lial cells. In the subsequent repair phase increased prolif-
eration and migration of endothelial and mesangial cells
is observed resulting in (partial) restoration of glomerular
structure and function. Using this model it was shown that
glomerular capillary repair is associated with a marked in-
crease in endothelial cell proliferation [12]. Several stud-
ies have provided evidence that circulating EPC may
contribute to glomerular capillary repair. Recent experi-
ments in our laboratory with rat hematopoietic chimeras
demonstrated low levels of bone marrow–derived cells
staining for the rat endothelial cell antigen RECA-1 [13].
The number of these cells gradually increased over time
suggesting that EPC contribute to normal physiologic
glomerular endothelial cell turnover. Following anti-Thy-
1.1–induced glomerular injury we observed a fourfold in-
crease in bone marrow–derived endothelial cells in the
glomeruli. These data indicate that glomerular repair can-
not only be attributed to migration and proliferation of
resident endothelial cells but also involves bone marrow–
derived cells.
Participation of circulating EPC to renal regeneration
has also been demonstrated in human adults. Williams
and Alvarez [14] were the first to report the presence
of acceptor endothelial cells in kidney allografts. Lagaaij
et al [15] reported that in human renal transplants the ex-
tent of replacement of donor endothelial cells lining the
peritubular capillaries by those of the acceptor was re-
lated to the severity of vascular injury. They suggested
that this endothelial replacement could be explained
by the involvement of acceptor-derived EPC. Recently,
our group demonstrated male, donor-derived endothe-
lial cells in the renal macrovasculature of a female pa-
tient who developed thrombotic microangiopathy after
gender-mismatched bone marrow transplantation [16].
Taken together these observations confirm a novel role
for bone marrow–derived endothelial cells in mainte-
nance and repair of renal endothelium.
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Mesangium
Glomerular mesangial cells provide structural capil-
lary support to the glomerulus and display a pericyte-
or smooth muscle cell–like phenotype. They play a
central role in the pathogenesis of a number of human and
experimental glomerular inflammatory diseases. In par-
ticular, mesangial hyperplasia is a prominent histopatho-
logic feature associated with impaired glomerular
function. Although transient hyperplasia is thought to
reflect a physiologic response required for successful
glomerular reconstitution and renal tissue repair, tight
regulation of mesangial proliferation, function, and apop-
tosis is needed for recovery without fibrosis.
Initially, mesangial maintenance and repair after in-
jury was thought to depend solely on proliferation of
viable resident intraglomerular mesangial cells. These
mature mesangial cells dedifferentiate before they pro-
liferate, as is described by El Nahas et al [17]. Like
the glomerular endothelial cells, in normal rats, mesan-
gial cell turnover amounts to less then 1% per day [3].
Hugo et al [18] demonstrated that during recovery of
anti-Thy1.1 glomerulonephritis, proliferating immature
mesangial cells migrated from the juxtaglomerular appa-
ratus and hilar region into the glomerulus.
Reminiscent to mesangial cell recruitment during em-
bryonic glomerulogenesis, the involvement of extra-
glomerular mesangial progenitor cells in glomerular
repair was reported by several investigators [19]. Ima-
sawa et al [5] demonstrated the involvement of bone
marrow–derived cells in normal mesangial cell turnover.
Lethally irradiated mice given transplants of T-cell–
depleted bone marrow cells from syngeneic donor trans-
genic for green fluorescent protein (GFP) manifested a
time-dependent increase in GFP-positive cells in their
glomeruli. When isolated and cultured, these cells stained
positive for the mesangial cell marker desmin and the
cells contracted in response to angiotensin II, confirm-
ing that bone marrow–derived cells have the potential to
differentiate into glomerular mesangial cells. Similar ex-
periments with mice transplanted with purified clonally
expanded hematopoietic progenitor cells were carried
out by Masuya et al [20] to confirm the hematopoietic
origin of bone marrow–derived mesangial cells.
In similar experiments, using a rat allogenic bone mar-
row transplant model and antibodies to the mesangial
cell–specific antigen Thy-1 (ox7), we confirmed this time-
dependent increase of bone marrow–derived mesangial
cells in the glomerulus [13]. Both Ito et al [21] and our
laboratory observed a major increase of bone marrow–
derived mesangial cells during recovery from anti-Thy-
1.1–induced mesangiolysis in bone marrow transplanta-
tion models in rats.
Cornacchia et al [22] demonstrated that glomeruloscle-
rosis can be transmitted by bone marrow transplanta-
tion in mice. Transplantation of bone marrow cells from
sclerosis-prone mice in normal background mice invoked
glomerulosclerosis in the recipients. These data not only
point to the contribution of bone marrow–derived cells
to glomerular maintenance and repair but also show that
dysfunctional or diseased mesangial progenitor cells can
have a negative influence on the kidney.
Tubules
The renal tubule is known for its high capacity for re-
generation. Acute tubular necrosis, as a result of ischemia
or toxic substances, can be followed by active migration
and proliferation to restore normal tissue architecture
and function [1]. Different sources of these proliferating
progenitor cells have been reported. Humes et al [23] iso-
lated resident proliferative epithelial cells from the tubuli
of mature rabbit kindeys and demonstrated that these
cells displayed a high capacity for self renewal and differ-
entiated into complete three-dimensional tubular struc-
tures in vitro. Similar experiments were later performed
with human epithelial cells [24].
Bone marrow–derived extrarenal tubular progenitor
cells were reported by Poulsom et al [4]. In female mouse
recipients of male bone marrow grafts colocalization
was observed of Y chromosomes and tubular epithelial
cell markers, suggesting participation of bone marrow–
derived cells in normal tubular cell turnover. The po-
tential importance of the role of bone marrow–derived
cells in tubular repair was demonstrated by Kale et al
[25]. When LacZ gene-positive bone marrow cells from
Rosa26 mice were transplanted into wild-type mice, re-
nal ischemia was associated with the occurence of LacZ-
positive (bone marrow–derived) tubular cells. It was esti-
mated that the majority of the tubular cells after tubular
repair were bone marrow–derived. Moreover, bone mar-
row ablation diminished functional recovery after tubu-
lar ischemia, while infusion of a progenitor cell reversed
this effect, suggesting an important functional role for the
hematopoietic stem cell in tubular repair.
Also in humans there are some indications for bone
marrow–derived tubular repair [26]. When male kidney
transplant patients who received a female kidney and
who recovered from acute tubular necrosis were stud-
ied, a Y chromosome could be demonstrated in few (less
than 1%) of the tubular cells. Although the functional
importance of this phenomenon in the human situation
is still dubious, these experiments do provide us with a
proof-of-principle observation on bone marrow–derived
tubular repair.
Fibroblasts
Renal fibrosis is a common denominator of most
chronic renal diseases that progress to end-stage renal
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failure and is associated with major alterations in the
tubular interstitial compartment. Increased numbers of
fibroblasts producing excessive amounts of extracellu-
lar matrix molecules characterize interstitial pathology.
Whether interstitial fibrosis is a cause or a consequence
of renal pathology remains unclear. Recently, it was hy-
pothesized that expansion of the cellular content of the
interstitium could be an attempt to restore an embryonic
environment supporting the repair of injured tubules [27].
Understanding the origin of interstitial fibroblasts may
well contribute to our understanding of the role of these
cells in renal pathology.
One hypothesis for the origin of interstitial fibroblasts
proposes an epithelial-mesenchymal transition in the lo-
cal formation of fibroblast from organ epithelium [28].
These transitions are particularly apparent during fibro-
genesis: fibrotic tissue repair following injury. Strutz et al
[29] first demonstrated de novo expression of a murine
fibroblast specific marker (FSP-1) in selected tubular ep-
ithelial cells during late stages of renal fibrogenesis. Ng
et al [30] showed that progressive renal failure is associ-
ated with the transdifferentiation of tubular cells into my-
ofibroblasts. A second hypothesis for the origin of adult
fibroblasts argues that marrow stromal cells are fibroblast
progenitors that shuttle from the bone marrow through
the circulation to populate peripheral organs. The pres-
ence of circulating fibroblast progenitor cells in animals
was shown in 1867 by Cohnheim [31]. When circulating
blood cells were labeled, they could be traced to sites of
active wound healing and displaying a fibroblastic mor-
phology. Bucala et al [32] described a distinct population
of human leukocytes that was able to differentiate into
fibroblasts. In an animal wound healing model, the ability
of fibroblast progenitor cells to home at sites of tissue in-
jury and participate in scar formation was demonstrated.
In a human study, Grimm et al [33] assessed the relative
participation of extrarenal derived a-actin–positive cells
in the kidney. In renal transplanted patients kidney biop-
sies were taken approximately 2 months after transplan-
tation. The amount of acceptor-derived a-actin–positive
cells in the kidney varied between 77% and 30%, indicat-
ing the existence of a circulating mesenchymal progenitor
cell.
Finally, Iwano et al [34] assessed the relative contri-
bution of fibroblasts from both origins to the interstitial
fibroblast content in normal and fibrotic murine kidneys.
In the normal kidney, bone marrow–derived cells were re-
sponsible for 12% of total renal fibroblasts, whereas the
remaining 88% were resident fibroblasts. In renal fibrosis,
as a consequence of unilateral ureteral obstruction, these
numbers were 15% and 49%, respectively. The remaining
36% was derived from epithelial-mesenchymal transdif-
ferentiation. Furthermore, they showed that these trans-
differentiated cells were actively involved in the fibrosis,
producing abnormal amounts and types of collagen.
CLINICAL IMPLICATIONS
Most therapies in renal medicine focus on reducing
renal damage. However, insight in renal repair and main-
tenance may offer new therapeutic strategies. As demon-
strated above, progenitor cells participate in renal repair
and turnover of the major renal cell types. Therefore,
renal progenitor cells may comprise a new target for ther-
apeutic strategies aimed at the reduction or even preven-
tion of renal disease.
Such strategies could be directed toward different pop-
ulations of progenitor cells. The advantage of circulating
progenitor cells may be that they are more accessible for
isolation in comparison to the resident progenitor cells.
Autologous progenitor cells from the patient are prefer-
able to allogenic progenitor cells because of possible re-
jection. Obviously, in case of inherited progenitor cell
disease, allogenic cells should be considered.
One approach to harness progenitor cells for therapeu-
tic purposes is to increase the available pool of progenitor
cells. Such expansion can be achieved by growth factor
therapy both in vivo and ex vivo. VEGF and erythro-
poietin are probably good candidates to stimulate pro-
genitor cell–mediated endothelial repair. Both have EPC
mobilizing and proangiogenetic activities [35, 36]. It was
shown that VEGF enhanced renal vascular repair in rats
with thrombotic microangiopathy and experimentally in-
duced glomerulonephritis [37]. Although a proliferative
effect on resident cells was shown, mobilization and stim-
ulation of circulating cells may also have been involved.
Next to in vivo growth factor therapy, the progenitor cell
pool can also be amplified by isolation of the progenitor
cells from the circulation or the kidney and expansion in
tissue cultures. Ex vivo expansion of progenitor cells has
already been performed by Weitzel, Fissell, and Humes
[24]. They isolated tubular progenitor cells from cadav-
eric kidneys and were able to expand these cells in vitro.
Another approach to enhance cellular repair and main-
tenance is reinforcement of progenitor cell function. EPC
dysfunction has been shown in diabetic mice [38]. The
decreased angiogenetic capacity of diabetic mice was
restored after infusion of EPC from nondiabetic mice.
Mesangial and mesangial progenitor cell dysfunction has
been described too (see above) [22, 39]. Replacement
of these prosclerotic cells by healthy allogenic mesangial
progenitor cells may potentially reduce or even prevent
progressive renal disease. The relatively low turnover rate
of mesangial cells of 1% per day might however hamper
this strategy [3]. Controlled mesangial injury by pharma-
cologic agents combined with healthy allogenic or trans-
fected autologous mesangial precursor cell infusion might
increase mesangial turnover and improve cell replace-
ment.
Finally, progenitor cells can be used as so-called “magic
bullets.” Progenitor cells are able to home and participate
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in their target tissue. This ability can be used to deliver cer-
tain gene products very locally. Gene therapy has already
successfully been used. Transfection of skeletal muscles
with the gene of a transforming growth factor-b1 (TGF-
b1) inhibitor was able to reduce glomerulosclerosis in a
rat nephritis model [40]. Transfection of renal progeni-
tor cells might provide a more local therapy, preventing
possible systemic side effects.
CONCLUSION
For most renal cell types, progenitor cells have now
been described. Besides a role in the normal cellular
turnover, progenitor cells are also involved in repair
processes. In contrast, dysfunctional progenitor cells can
hamper repair or even actively inflict damage. These char-
acteristics make these cells interesting as therapeutic tar-
gets either by increasing their number or by improving
their function.
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